Proteomics in diabetic kidney disease

Published on March 30, 2023   40 min

Other Talks in the Series: The Kidney in Health and Disease

Please wait while the transcript is being prepared...
Hello, I'm Peter Rossing, I'm a Professor at University of Copenhagen in Denmark and also Head of complications researchers Steno Diabetes Copenhagen. I'm going to talk about proteomics in diabetic kidney disease.
First, I'll share my disclosures. I worked with different pharmaceutic companies in relation to clinical trials. Some of them are relevant for today, but most of them are not.
Diabetes is a major problem globally. Currently, 463 million people are estimated to have diabetes in 2019. And this was expected to rise to more than 700 million in 2045. These numbers are rising all over the world. Approximately 90 percent of those with diabetes have type two diabetes. With more people having diabetes, more people are at risk for kidney disease due to diabetes. It's estimated that approximately 40 percent of those with diabetes have some degree of chronic kidney disease. With more people having diabetes, more people have chronic kidney disease. Diabetes is actually unfortunately, so far the leading cause of kidney failure around most of the world.
We need to look out for chronic kidney disease or diabetic kidney disease in people having diabetes. As there are no symptoms, this has to rely on systematic screening. Therefore, the American Diabetes Association and K-deal and organization issuing guidelines for treatment of people with chronic kidney disease have made a consensus guidelines saying we need to treat and screen everybody for kidney disease on a yearly basis. If there's signs of kidney damage, that is increased albumin creatinine ratio or impaired kidney function that is estimated glomerular filtration rate, or a combination of this, well then we need start intervention if these impairments in albuminuria or GFR can be confirmed and are sustained for more than three months. This has become particularly important because we have now today more treatment opportunities than we've had in the past than just during very recent times more treatment opportunities have become apparent.